Induction of tumor infiltrating immune cells through regulation of tumor microenvironment and its application for novel cancer immunotherapy
| Project/Area Number |
16K15601
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Kanagawa Cancer Center Research Institute |
|---|
Principal Investigator |
Sasada Tetsuro 地方独立行政法人神奈川県立病院機構神奈川県立がんセンター(臨床研究所), がんワクチンセンター, 部長 (70293967)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
大竹 淳矢 地方独立行政法人神奈川県立病院機構神奈川県立がんセンター(臨床研究所), その他部局等, 技師・研究員 (10758915)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 腫瘍浸潤免疫細胞 / ケモカイン / サイトカイン / 異所性リンパ様組織 / がん免疫療法 |
|---|
| Outline of Final Research Achievements |
The aim of this study was to develop the method to efficiently induce infiltration of immune cells and formation of ectopic lymphoid structures within tumor tissues through artificial modulation of tumor microenvironment. This study examined the effects of chemokines, CCL21 and CXCL13, on tumor growth and immune cell infiltration in murine tumor models. The murine tumor cell lines transfected with CCL21 or CXCL13 showed retardation of tumor growth when implanted into mice, resulting in prolongation of survival of tumor-bearing mice. In addition, they induced infiltration of T cells and B cells within tumor tissues, but did not develop ectopic lymphoid structures. We will further investigate the effects of other chemokines and cytokines on tumor growth and immune cell infiltration and identify the methods to artificially develop ectopic lymphoid structures within tumor tissues.
|
Report
(3 results)
Research Products
(25 results)
-
-
-
[Journal Article] Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma.2017
Author(s)
Suekane S, Ueda K, Nishihara K, Sasada T, Yamashita T, Koga N, Yutani S, Shichijo S, Itoh K, Igawa T, Noguchi M.
-
Journal Title
Cancer Science
Volume: 108
Pages: 2430-2437
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
[Journal Article] A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer.2017
Author(s)
Shirahama T, Muroya D, Matsueda S, Yamada A, Shichijo S, Naito M, Yamashita T, Sakamoto S, Okuda K, Itoh K, Sasada T, Yutani S.
-
Journal Title
Cancer Science
Volume: 印刷中
Pages: 838-845
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele.2017
Author(s)
Sakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Naitou M, Sasada T, Hattori N, Kohno N, Itoh K.
-
Journal Title
Cancer Science
Volume: 印刷中
Pages: 598-603
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer.2017
Author(s)
Sakamoto S, Yamada T, Terazaki Y, Yoshiyama K, Sugawara S, Takamori S, Matsueda S, Shichijo S, Yamada A, Noguchi M, Itoh K, Hattori N, Kohno N, Sasada T.
-
Journal Title
Clinical Lung Cancer
Volume: 印刷中
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females.2017
Author(s)
Yokomine M, Matsueda S, Kawano K, Sasada T, Fukui A, Yamashita T, Komatsu N, Shichijo S, Tasaki K, Matsukuma K, Itoh K, Kamura T, Ushijima K.
-
Journal Title
Exp Ther Med.
Volume: 13
Pages: 1500-1505
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
[Journal Article] Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer.2016
Author(s)
Takayama K, Sugawara S, Saijo Y, Maemondo M, Sato A, Takamori S, Harada T, Sasada T, Kakuma T, Kishimoto J, Yamada A, Noguchi M, Itoh K, Nakanishi Y.
-
Journal Title
J Immunol Res
Volume: 2016
Pages: 1745108-1745108
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
